Head-to-head comparison of [68Ga]Ga-FAPI-04 PET and [18F]FDG PET in the detection of cancer recurrence: a systematic review and meta-analysis.

ABSTRACT

Background: The comparative diagnostic performance of [68Ga]Ga-fibroblast activation protein inhibitors-04 {[68Ga]Ga-FAPI-04} positron emission tomography (PET) and fluorodeoxyglucose F 18 {[18F]FDG} PET in identifying cancer recurrence remains uncertain. The purpose of our study was to compare the diagnostic performance of [68Ga]Ga-FAPI-04 PET and [18F]FDG PET imaging in cancer recurrence. Methods: Up until March 1, 2024, we searched PubMed, Embase, and Web of Science for pertinent papers. Studies examining the diagnostic utility of [68Ga]Ga-FAPI-04 PET and [18F]FDG PET for cancer recurrence were included. Using a bivariate fixed-effect model and random-effect model, the pooled sensitivity and specificity for [68Ga]Ga-FAPI-04 PET and [18F]FDG PET were reported as estimates with 95% confidence intervals (CIs). The I2 statistic was used to evaluate the heterogeneity among the pooled studies. The included studies' quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) approach. Results: In all, 508 papers were found during the first search; ultimately, 12 studies totaling 224 patients were included. The pooled sensitivity of [68Ga]Ga-FAPI-04 PET and [18F]FDG PET for cancer recurrence were 0.97 (95% CI 0.90-1.00) and 0.69 (95% CI 0.60-0.77). The pooled sensitivity of [68Ga]Ga-FAPI-04 PET and [18F]FDG PET for gastrointestinal cancer recurrence were 1.00 (95% CI 0.97-1.00) and 0.57 (95% CI 0.42-0.74). The pooled specificity of [68Ga]Ga-FAPI-04 PET and [18F]FDG PET for gastrointestinal cancer recurrence were 0.66 (95% CI 0.15-1.00) and 0.46 (95% CI, 0.00-1.00). Conclusions: Based on the previous studies, [68Ga]Ga-FAPI-04 PET shows higher sensitivity compared to [18F]FDG PET in detecting tumor recurrence, especially in detecting gastrointestinal cancer recurrence. [68Ga]Ga-FAPI-04 PET shows similar specificity compared to [18F]FDG PET in detecting gastrointestinal cancer recurrence. The detection results, however, came from investigations using modest sample numbers. In this matter, more extensive prospective study is required.